ライフサイエンスコーパス: confidence interval

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します

1 ing the reporting odds ratios (ROR) with 95% confidence intervals.

2 DP were clearly attenuated, albeit with wide confidence intervals.

3 esent seroprevalence point estimates and 95% confidence intervals.

4 relative risk (RR) estimates and associated confidence intervals.

5 ls were used to estimate odds ratios and 95% confidence intervals.

6 OPF (10.7% vs 35.5%, P < 0.001; OR 0.20, 95% confidence interval 0.12-0.33).

7 e wound complications (Odds Ratio 0.400 [95% confidence interval 0.168, 0.954], p = 0.039).

8 er the receiver operating curve of 0.81 (95% confidence interval = 0.69-0.93).

9 baseline, 3 months, 6 months; R = 0.95-0.97, confidence interval = 0.94-0.97) indicating little time-

10 otor scores at 4.5 years (beta = -0.095, 95% confidence interval = -0.184 to -0.005), with a standard

11 risk for retreatment (odds ratio, 0.26; 95% confidence interval, 0.04-0.99; P = .05).

12 dds ratio, 0.26 for group 2 vs. group 1; 95% confidence interval, 0.09-0.74).

13 dds ratio, 0.39 for group 2 vs. group 1; 95% confidence interval, 0.16-0.95) and almost 4-times lower

14 6B plasma detection (hazard ratio, 0.40; 95% confidence interval, 0.20-0.80).

15 r-negative patients (hazard ratio, 0.49; 95% confidence interval, 0.280-0.86; P = .0096).

16 ment of bronchiectasis (difference, 0.9; 95% confidence interval, 0.3-1.6; P = 0.003) and Aspergillus

17 kidney from donors >=80 years was 0.54 (95% confidence interval, 0.38-0.77; P < 0.0001).

18 3 to 8 years (adjusted odds ratio, 0.73; 95% confidence interval, 0.57-0.93).

19 different (adjusted hazard ratio, 1.07; 95% confidence interval, 0.68-1.68; P = 0.76).

20 .98) compared with pleural pH (AUC 0.82; 95% confidence interval, 0.73-0.90).

21 bility of retinal reattachment was 0.84 (95% confidence interval, 0.77-0.91).

22 ib (10.2 and 9.2 mo [hazard ratio, 0.91; 95% confidence interval, 0.78-1.05]).

23 48-72 hours (adjusted odds ratio, 0.87; 95% confidence interval, 0.79-0.94).

24 94 children [26%]; relative risk, 1.03; 95% confidence interval, 0.81 to 1.32; P = 0.80).

25 h an area under the curve (AUC) of 0.93 (95% confidence interval, 0.89-0.98) compared with pleural pH

26 ed with standard care (odds ratio, 2.07; 95% confidence interval, 0.98-4.40; P = 0.058).

27 rease in the lung volume of exhaled air (95% confidence interval, -0.17 to -0.07; P = 6.62 x 10(-8))

28 ifference between proportions was 0.87% (95% confidence interval, -0.84% to 2.59%).

29 ll, odds of death from MI increased 34% (95% confidence interval: 0%, 80%) on days with heavy snowfal

30 /rehospitalizations (hazard ratio: 0.39; 95% confidence interval: 0.19 to 0.83; p = 0.01).

31 nd 21% with placebo (relative risk: 0.6; 95% confidence interval: 0.3-1.3; P = .23).

32 nse Compact membership (Odds Ratio=0.51; 95% Confidence Interval: 0.32-0.80) was associated with lowe

33 iting list (adjusted hazard ratio: 0.58; 95% confidence interval: 0.36-0.95; P = 0.03).

34 LDL-C was <70 mg/dl (hazard ratio: 0.61; 95% confidence interval: 0.40 to 0.91; p = 0.016), whereas C

35 % vs. 9.7%; adjusted hazard ratio: 0.61; 95% confidence interval: 0.53 to 0.71; p < 0.001).

36 adjusted hazard ratio for females: 0.90 [95% confidence interval: 0.54 to 1.51]; adjusted hazard rati

37 ; adjusted hazard ratio for males: 0.76 [95% confidence interval: 0.56 to 1.02]; p for interaction =

38 an area under the curve (AUC) of 0.694 (95% Confidence Interval: 0.612-0.776) and classified correct

39 EA, quintile5 vs. 1 hazard ratio = 0.79, 95% confidence interval: 0.64, 0.98, and BH-adjusted Ptrend

40 vs. 11.2%; adjusted hazard ratio: 0.77; 95% confidence interval: 0.68 to 0.88; p < 0.001) and all-ca

41 NC, quintile5 vs. 1 hazard ratio = 0.81, 95% confidence interval: 0.71, 0.92, and BH-adjusted Ptrend

42 %) and 0.740 in the contemporary cohort (95% confidence interval: 0.723-0.758; sensitivity 81%, speci

43 decreased rate of PD (rate ratio = 0.83, 95% confidence interval: 0.75, 0.91) compared with no use.

44 diabetes of 0.766 in the primary cohort (95% confidence interval: 0.750-0.782; sensitivity 75%, speci

45 ce of AS-CA (area under the curve: 0.86; 95% confidence interval: 0.78 to 0.94; p < 0.001).

46 HF hospitalization (hazard ratio: 0.86; 95% confidence interval: 0.81 to 0.92; p < 0.001), with no s

47 operating characteristic curve of 0.89 (95% confidence interval: 0.82, 0.96) and an area under the p

48 ed hazard ratio: 0.91 per -5 mm Hg PASP; 95% confidence interval: 0.86 to 0.96; p = 0.0009).

49 RW-BMO values from all sectors was 0.95 (95% confidence interval: 0.86-1.00).

50 ompromised [4-year relative survival and 95% confidence interval: 0.87 (0.85-0.89), 0.87 (0.86-0.88),

51 ADHD in offspring (hazard ratio = 1.00, 95% confidence interval: 0.88, 1.14).

52 with DACLD (adjusted hazard ratio, 1.4; 95% confidence interval: 0.9, 1.9; P = .17).

53 nder the precision-recall curve of 0.96 (95% confidence interval: 0.93, 0.99).

54 between the 2 groups (odds ratio: 1.18; 95% confidence interval: 0.99 to 1.41; p = 0.26).

55 biopsy-proven acute rejection (hazard ratio [confidence interval], 0.32 [0.11-0.90], P = 0.031 at uni

56 ith: being male (hazard ratio (HR) 1.59 (95% confidence interval 1.53-1.65)); greater age and depriva

57 conservative group (mean difference 9.7, 95% confidence interval 1.7-17.7, P = 0.018), which approach

58 illus with trapped air (difference, 3.2; 95% confidence interval, 1.0-5.4; P = 0.004).

59 stational-age infants (odds ratio, 1.15; 95% confidence interval, 1.06, 1.24); conversely, there was

60 er risk of amputation (risk ratio, 1.80; 95% confidence interval, 1.07-3.01), as was the presence of

61 ant outcomes (marginal relative risk and 95% confidence interval, 1.161.501.95).

62 -30.6; MLH1: P = 0.04; odds ratio, 25.4; 95% confidence interval, 1.2-143; SMARCE1: P = 0.001; odds r

63 , and paternal origin (adjusted HR, 3.2; 95% confidence interval, 1.3 to 7.7).

64 (>=358 pg/mL) had an OR for VTE of 2.05 (95% confidence interval, 1.37-3.08) compared with those with

65 was seen for diabetes (rate ratio, 1.55; 95% confidence interval, 1.48-1.61).

66 trols (PALB2: P = 0.02; odds ratio, 8.9; 95% confidence interval, 1.5-30.6; MLH1: P = 0.04; odds rati

67 for deprivation (adjusted odds ratio 4.0 95% confidence interval, 1.7-10.6).

68 aged 30-49 years at enrollment to 1.13 (95% confidence interval: 1.02, 1.26) in those aged 70-89 yea

69 ratios per standard deviation were 1.10 (95% confidence interval: 1.05, 1.16) and 1.15 (1.10, 1.19) f

70 ompensation (adjusted hazard ratio, 3.7; 95% confidence interval: 1.1, 12.6; P = .04), but not for fu

71 y with age at BMI assessment, from 1.25 (95% confidence interval: 1.18, 1.33) in persons aged 30-49 y

72 io for each 10-ms decrease in EMW: 1.37; 95% confidence interval: 1.27 to 1.48; p < 0.0001).

73 equent MI or stroke (hazard ratio: 1.34; 95% confidence interval: 1.28 to 1.40) and major amputation

74 with DACLD (adjusted hazard ratio, 3.8; 95% confidence interval: 1.7, 9.5; P = .004).

75 ion group (baseline-adjusted difference [95% confidence interval] -1.91 minutes [-5.53 to 1.70], p =

76 d 42% in the LBT arm (odds ratio, 28.72; 95% confidence interval, 10.27-80.31).

77 18 and 30 (adjusted relative risk, 0.30 [95% confidence interval, .12-.74]; P = .010).

78 number compared to non-WASH arms, -0.07 [95% confidence interval, -.14 to -.02]), but had no statisti

79 /330 (53.6%; percentage decrease, 26.5%; 95% confidence interval, 18.7-34.1) with no change in the ca

80 etween 60-80% long shifts was 15% lower (95% confidence interval 2% to 27%) than with all long shifts

81 ed with strain sharing (odds ratio 8.50; 95% confidence interval 2.2 - 33.4, P = 0.002).

82 1 kPa or more (adjusted odds ratio, 4.8; 95% confidence interval, 2.0-11.8).

83 ith increased 30-day mortality (OR, 8.4 [95% confidence interval, 2.23-31.7]).

84 with CACLD (adjusted hazard ratio, 7.4; 95% confidence interval: 2.7, 20.2; P < .001) and those with

85 idence interval 38.5-75.5) vs 33 months (95% confidence interval 20.3-45.7), P = 0.03].

86 ther factors (adjusted odds ratio: 0.41; 95% confidence interval, .22 - .77).

87 At 1 year, RYGB patients had 28.4%TWL (95% confidence interval: 28.2, 28.5), SG 23.0%TWL (22.8, 23.

88 IPD cases, we observed a 35.3% decrease (95% confidence interval, 29.2%-41.8%]) and the median age sh

89 had higher incidences of diabetes (4.74 [95% confidence interval, 3.09-7.27] vs 0.87 [.42-1.83] per 1

90 east square means difference: 3.9 mm(2); 95% confidence interval: 3.3 to 4.5; p < 0.0001).

91 irth weight was associated with 5.2 mum (95% confidence interval: 3.3-7.0) increase in RNFL thickness

92 ies resulted in a primary outcome (7.4%; 90% confidence interval: 3.4% to 15.9%).

93 ected participants (half-life, infinity; 95% confidence interval, 309 years to infinity) but declined

94 ot confer a survival benefit [57 months (95% confidence interval 38.5-75.5) vs 33 months (95% confide

95 had ASN corresponding to at least 9.18% (95% confidence interval 4.29%-16.72%).

96 er times for a 3-kilometer run (beta and 95% confidence intervals =4.93 (1.61, 8.25) and 4.65 (2.20,

97 occlusion for a score above 3 was 16.3 (95% confidence interval: 4.1 to 65.3; p < 0.0001).

98 ed with clinical outcomes (hazard ratio [95% confidence interval], 4.8 [2.6-9.0], P < 0.01) when comp

99 Three-year OS was 55.5% (95% confidence interval, 40.8-68.0).

100 3; SMARCE1: P = 0.001; odds ratio, 2047; 95% confidence interval, 52-4.5e15, respectively).

101 and SoC approaches was 26 of 34 (76.5%, 95% confidence interval = 58.8-89.3%) in <4 months, greater

102 their diagnoses for 72% of the patients (95% confidence interval = 60-85%); chance-adjusted agreement

103 survey, VE against HPV-16/18 was 89.9% (95% confidence interval, 63.0%-97.2%).

104 erval, 80%-98%) and specificity was 82% (95% confidence interval, 68%-91%).

105 4-year cumulative probability being 9% (95% confidence interval 7%-12%).

106 l revascularization (hazard ratio: 8.13; 95% confidence interval: 7.96 to 8.29).

107 terval, 81%-95%) and specificity of 85% (95% confidence interval, 71%-93%).

108 is, positive predictive value was 93.3% (95% confidence interval, 77.6%-99.2%) by histopathologic val

109 1.9%/year, with 10-year survival of 85% (95% confidence interval: 77% to 94%).

110 for heart failure (hazard ratio, 11.40; 95% confidence interval, 8.38 to 15.50), followed by coronar

111 dies, 151 lesions), sensitivity was 93% (95% confidence interval, 80%-98%) and specificity was 82% (9

112 ions) demonstrated a sensitivity of 90% (95% confidence interval, 81%-95%) and specificity of 85% (95

113 ficant trend (adjusted odds ratio, 1.44; 95% confidence interval, .81-2.56).

114 nfavorable outcome and 98 patients (90%; 95% confidence interval, 83 to 95) had a favorable outcome.

115 of 53 patients (94% diagnostic accuracy; 95% confidence interval, 84%-99%).

116 and year of admission (odds ratio, 0.97; 95% confidence interval, .85-1.12; P = .71).

117 fied all pN1 patients (100% sensitivity; 95% confidence interval, 86%-100%) and performed correct nod

118 by histopathologic validation and 96.2% (95% confidence interval, 86.3%-99.7%) by the combination of

119 justed incidence rate ratio [aIRR] 1.12, 95% confidence interval [95% CI] 1.11-1.13, p < 0.001, per d

120 ed risk of CKD (hazard ratio [HR], 1.51; 95% confidence interval [95% CI], 1.08 to 2.10), which was a

121 63 [59%] patients; odds ratio [OR], 2.7; 95% confidence interval [95% CI], 1.6 to 3.8; P=0.02) as wel

122 rhosis (adjusted odds ratio [aOR], 2.67; 95% confidence interval [95% CI], 2.30 to 3.08), and ESKD (a

123 a 9.15-fold increase in the odds of AKI (95% confidence interval [95% CI], 3.64 to 22.93) and a 22.86

124 K6 5-12: adjusted odds ratio [AOR] 0.86, 95% confidence interval [95%CI] 0.82, 0.90; K6 >= 13: AOR 0.

125 lysis, variables (subhazard ratio [SHR] [95% confidence interval]) associated with developing clinica

126 e overall mean IOP change was -0.5 mmHg (95% confidence interval CI, -0.6 to -0.3 mmHg) at 12 months

127 with polyhexanide [odds ratio (OR) 0.44; 95% confidence interval (CI) 0.27-0.72; P = 0.001) was assoc

128 isease [incidence rate ratio (IRR) 1.17; 95% confidence interval (CI) 0.76-1.63; P = 0.467], but ther

129 the relative risk (RR) of FTR was 0.84, (95% confidence interval (CI) 0.78-0.90) after implementation

130 than sleeve gastrectomy (SG; 64.5%; RR 0.92, confidence interval (CI) 0.86-0.99) and adjustable gastr

131 eferred to the ED [odds ratio (OR) 1.32, 95% confidence interval (CI) 1.09-1.60].

132 of product with any "high in" (from 51% [95% confidence interval (CI) 49-52] to 44% [95% CI 42-45]),

133 After adjustments, WLZ-O had 89 g (95% confidence interval (CI) 5; 172) lower FFM compared to M

134 pooled estimates of sensitivity (84.8%; 95% confidence interval (CI) = 81.4-87.8%) and specificity (

135 We examine the bias, confidence interval (CI) coverage, and bias-variance tra

136 ng to estimate the hazard ratio (HR) and 95% confidence interval (CI) for the association of CRC diag

137 we found no group difference (d = 0.03 [95% confidence interval (CI), -0.20 to 0.26], z = 0.28, p =

138 the internal validation cohort of 0.76 [95% confidence interval (CI), 0.72 to 0.79] for AKI, 0.79 (9

139 drops [area under the curve (AUC), 0.93; 95% confidence interval (CI), 0.87-1.00].

140 clude tobacco use (odds ratio (OR), 2.0; 95% confidence interval (CI), 1.2-3.4, P = 0.009), coronary

141 ighest vs. lowest quartile of FLI),1.63; 95% confidence interval (CI), 1.23-2.16; P = 0.001 for trend

142 al tumor in 37 of 208 women [FNR, 17.8%; 95% confidence interval (CI), 12.8-23.7%].

143 h AD eyes in mild glaucoma (mean, 42.2% [95% confidence interval (CI), 41.2%-43.2%] and 46.5% [95% CI

144 rather than subjective assessments (54% [95% confidence interval (CI), 51-57%] vs. 35% [95% CI, 29-41

145 e used to estimate hazard ratio (HR) and 95% confidence interval (CI).

146 3, and TT3 [absolute difference: - 0.62; 95% confidence interval (CI): - 0.12, - 0.01; p = 0.04; abso

147 th an increase of MI 6 h later by 3.27% [95% confidence interval (CI): 0.27, 6.37], 5.71% (95% CI: 1.

148 nation with 1, 2, and 3 doses were 0.53 (95% confidence interval (CI): 0.37, 0.76; VE = 47%), 0.45 (9

149 rols (mean difference (MD) = 0.59 units, 95% confidence interval (CI): 0.39, 0.80), lower physical ac

150 d survival [adjusted hazard ratio 0.61; (95% confidence interval (CI): 0.50-0.76)].

151 d with ALL risk (odds ratio (OR) = 0.85, 95% confidence interval (CI): 0.60, 1.21).

152 er (cc)] relative UFP exposure was 1.04 [95% confidence interval (CI): 1.02, 1.06].

153 sed odds of LBW [odds ratio (OR) = 1.40, 95% confidence interval (CI): 1.14, 1.71] and SGA (OR = 1.22

154 and were highest in Oceania with 1.33% (95% confidence interval (CI): 1.16 - 1.49%) of total fatty a

155 ees of malnutrition, respectively: 2.02 [95% confidence interval (CI): 1.65 to 2.49] and 3.65 [95% CI

156 udy areas (overall incidence rates 12.5 [95% confidence interval (CI): 11.2, 14.1] and 871.1 [95% CI:

157 nd >39.0 years were associated with 22% (95% confidence interval (CI): 14, 30), 25% (95% CI: 17, 33),

158 DM in men aged 64 years or younger (OR [95% confidence interval (CI)], 1.71 [1.03-2.85]; P-value = 0

159 mood disorder (adjusted ratio of means [95% confidence interval (CI)]: 1.40 [0.99, 1.98]), reporting

160 Odds ratios (OR) with 95% confidence intervals (CI) for sarcopenia were higher for

161 Seroprevalence 95% confidence intervals (CI) were adjusted for assay sensit

162 The mean costs per patient were US $847 (95% confidence interval [CI] $776-927) for FLU+5FC, and US $

163 ndardised mean difference [SMD] = -0.82, 95% confidence interval [CI] -1.02 to -0.63) and active cont

164 These changes led to a -96.1 ml (95% confidence interval [CI] -144.2 to -48.0) reduction in v

165 (incidence rate = 0.28/person-year [PY], 95% confidence interval [CI] 0.22-0.35/PY).

166 , colorectal cancer incidence was 0.55% (95% confidence interval [CI] 0.40-0.75) with low-performing

167 ence (subdistribution hazard ratio 0.91, 95% confidence interval [CI] 0.49-1.67, p=0.76) and the rate

168 y 24% (hazard ratio [HR] per year 0.976; 95% confidence interval [CI] 0.959-0.993).

169 neonates were heavier at birth (58.20 g, 95% confidence interval [CI] 10.10-106.31, p = 0.02) with in

170 e rates per 1000 person-years were 20.6 (95% confidence interval [CI] 19.6-21.6) among untreated pers

171 y overweight or obesity (MUOO) (HR 2.22, 95% confidence interval [CI] 2.00-2.47, p < 0.001) and trans

172 hallenge (adjusted odds ratio [OR] 3.81, 95% confidence interval [CI] 2.49 to 5.86) and added a signi

173 nd 696 young women (20-24 years), 31.7% (95% confidence interval [CI] 29.5-34.1), of whom were displa

174 4 to 8 (P = .004, odds ratio [OR] 31.3, 95% confidence interval [CI] 3.0 to 329) and cumulative RFI

175 nosis of melanoma (odds ratio [OR] 5.01; 95% Confidence Interval [CI] 3.50-7.61) and kidney cancer (O

176 ll, uBPA concentrations were 86% higher (95% confidence interval [CI] 42% to 143%, P < 0.001) at 2 d

177 sensitivity for buccal samples was 51% (95% Confidence Interval [CI] 42-60%).

178 st 4 weeks after IE diagnosis (HR 57.20, 95% confidence interval [CI] 45.58-71.78; P < .0001) and a m

179 nths of progression-free survival (PFS) (95% confidence interval [CI] 5-29, 49-69 versus 70-82 months

180 ce standard, CrAgSQ was 93.0% sensitive (95% confidence interval [CI] 80.9% to 98.5%) and 93.8% speci

181 f PCR-adjusted ACPR at Day 42 was 96.1% (95% confidence interval [CI] 91.4-98.2; Kaplan-Meier).

182 = 57%, adjusted odds ratio [aOR] = 1.91, 95% confidence interval [CI] = 0.40-9.01, p = 0.41).

183 CH (vs 0-3 days; odds ratio [OR] = 1.49, 95% confidence interval [CI] = 0.50-4.43), nor did they have

184 cantly lower for African-American (0.67; 95% confidence interval [CI] = 0.58 to 0.78) and Hispanic or

185 tal cholesterol (odds ratio [OR] = 0.92; 95% confidence interval [CI] = 0.85-0.99; p = 0.03) and LDL

186 e at 3 years (relative risk [RR] = 3.49, 95% confidence interval [CI] = 1.10-11.1, p = 0.03 and RR =

187 ly active lesions contain 64% more iron (95% confidence interval [CI] = 17-127%, p = 0.004) than immu

188 ncrease in WHR there was a 75% increase (95% confidence interval [CI] = 44-113%) in risk for large ar

189 creased from 0.00 after 5 years to 0.22 (95% confidence interval [CI], -0.01 to 0.67) after 30 years.

190 ents were: ME from RVO, -0.56 (774 eyes; 95% confidence interval [CI], -0.61 to -0.51; P < 0.001); DM

191 usted difference, 0.7 percentage points; 95% confidence interval [CI], -0.9 to 2.4) - a result that s

192 e placebo group was 2 percentage points (95% confidence interval [CI], -18 to 27) for the 20-mg dose,

193 lesterol level was a reduction of 39.7% (95% confidence interval [CI], -43.7 to -35.7) in the inclisi

194 tive NPS and saliva specimens was -3.61 (95% confidence interval [CI], -5.78 to -1.44; P = 0.002).

195 he crude mean VA change of +1.5 letters (95% confidence interval [CI], 0-3.1 letters) in the ranibizu

196 ried by world region, from 2.6% in Asia (95% confidence interval [CI], 0-5.9) to 10.5% in Australia (

197 ated with an increase of 0.024 mBq/m(3) (95% confidence interval [CI], 0.020, 0.028 mBq/m(3)) in the

198 r more VA gain was 0.49 events/eye-year (95% confidence interval [CI], 0.26-0.86 events/eye-year), wh

199 from baseline to month 24 was +0.36 mm (95% confidence interval [CI], 0.27-0.45 mm) for ranibizumab

200 subdistribution hazard ratio [sHR] 0.74; 95% confidence interval [CI], 0.40-1.34; P = 0.38) and death

201 of age vs. 66-70 years of age: OR, 0.49; 95% confidence interval [CI], 0.48-0.50), whereas women were

202 er 100 person-years; hazard ratio, 0.69; 95% confidence interval [CI], 0.57 to 0.83; P<0.001).

203 this was not statistically significant (95% confidence interval [CI], 0.57-3.06; P = 0.51).

204 years of age showed a myopia OR of 0.65 (95% confidence interval [CI], 0.63-0.67; P < 10(-205)) and 0

205 0.9 per nanograms per milliliter of PSA; 95% confidence interval [CI], 0.8, 0.9; P < .001).

206 the placebo group (hazard ratio, 0.97; 95.6% confidence interval [CI], 0.85 to 1.11; P<0.001 for noni

207 opioid injecting (odds ratio [OR], 0.95; 95% confidence interval [CI], 0.92-0.99) and sharing (OR, 0.

208 rse OS and DFS (OS: hazard ratio [HR], 0.98; confidence interval [CI], 0.97-1.00; P = 0.013; DFS: HR,

209 cases from controls with AUCs of 0.992 (95% confidence interval [CI], 0.983 to 1.000) and 0.984 (95%

210 were age at LT (hazard ratio [HR], 1.04; 95% confidence interval [CI], 1.01-1.07), male gender (HR, 2

211 r tumor diameter (odds ratio [OR], 1.15, 95% confidence interval [CI], 1.03-1.30) and alpha-fetoprote

212 transformation (odds ratio [OR], 3.729; 95% confidence interval [CI], 1.099-12.649; P = 0.035).

213 tters) were least squares means of +1.1 (95% confidence interval [CI], 1.0;1.3), -1.3 (95%CI, -1.5;-1

214 acular atrophy (hazard ratio [HR], 1.70; 95% confidence interval [CI], 1.17-2.49; P = 0.006).

215 years (adjusted odds ratio [aOR], 1.75; 95% confidence interval [CI], 1.18, 2.60, P = .01), AA ident

216 th (age-adjusted odds ratio [aOR], 1.50; 95% confidence interval [CI], 1.19-1.88), preterm premature

217 1000 patient-days; relative risk, 1.53; 95% confidence interval [CI], 1.37 to 1.72; P<0.001).

218 early morning IOP increase of 4.3 mmHg (95% confidence interval [CI], 1.4-7.3; P = 0.005) and mean i

219 immunogenicity (hazard ratio [HR], 1.90; 95% confidence interval [CI], 1.60-2.25; P = 5.88 x 10(-13))

220 the average RNFL thickness was 2.5 mum (95% confidence interval [CI], 1.8-3.1 mum), 2.8 mum (95% CI,

221 both neovascular (hazard ratio, 11.036; 95% confidence interval [CI], 1.807-67.393) and total (hazar

222 s, this signature achieved a PPV of 50% (95% confidence interval [CI], 15.7-84.3) and negative predic

223 dults was 1772 per 100 000 person-years (95% confidence interval [CI], 1754-1789) and 303 per 100 000

224 jects with TLs (hazard ratio [HR] = 8.5; 95% confidence interval [CI], 3.1-23; P < .001).

225 centage points (upper boundary of the 98.75% confidence interval [CI], 3.3), and that between the 20-

226 io [HR] for <50 vs >=500 cells/uL, 13.4; 95% confidence interval [CI], 3.5-51.0) and proportion of ti

227 Hepatitis C virus infection (OR, 15.84; 95% confidence interval [CI], 4.06-61.87; P < 0.001) was the

228 Only 12.8% (5/39; 95% confidence interval [CI], 4.3%-27.4%) of patients vaccin

229 task had 11.2 times the odds of frailty (95% confidence interval [CI], 5.2-23.9), 2.6 times the odds

230 e percentage who had a response was 69% (95% confidence interval [CI], 55 to 81), and 1-year progress

231 caused an estimated 622,390 infections (95% confidence interval [CI], 579,125 to 665,655) among hosp

232 psy 1, mean %HCV-infected cells = 25.2% (95% confidence interval [CI], 7.4%-42.9%), correlating with

233 external validation cohorts were 83.5% (95% confidence interval [CI], 75.4-90.7%) and 91.9% (95% CI,

234 Overall survival was 83.3% (95% confidence interval [CI], 76.2-88.4) at 1 year posttrans

235 inal swabs and urine samples were 96.6% (95% confidence interval [CI], 88.5 to 99.1%) and 86.4% (95%

236 wing doxycycline-azithromycin was 95.4% (95% confidence interval [CI], 89.7-98.0) and doxycycline-mox

237 ge [IQR], 0.22 to 1.46 cp/ml) and a 14% (95% confidence interval [CI], 9% to 19%) decline in viral lo

238 pretreatment LI-RADS category was 0.40 (95% confidence interval [CI]: 0.15, 0.67; P < .01) and was l

239 om-effects meta-analyses and were 0.32% (95% confidence interval [CI]: 0.26% to 0.39% [corresponding

240 medical mistrust (odds ratio [OR]: 0.59; 95% confidence interval [CI]: 0.39, 0.91), experienced discr

241 CV readmission (hazard ratio [HR]: 0.76; 95% confidence interval [CI]: 0.62 to 0.94, and HR: 0.74; 95

242 AUC) for the image-based model was 0.73 (95% confidence interval [CI]: 0.71, 0.74).

243 s placebo drug (hazard ratio [HR]: 0.87; 95% confidence interval [CI]: 0.76 to 0.98; p = 0.028).

244 BL arm adjusted odds ratio [AOR] = 1.00, 95% confidence interval [CI]: 0.77-1.30, p = 0.973; women's

245 onfibrotic (CPA <=4.8%) livers was 0.95 (95% confidence interval [CI]: 0.91, 1.00) for EP-3533, follo

246 rating characteristic curve [AUC], 0.97; 95% confidence interval [CI]: 0.94, 1.00) and excellent inte

247 vs 23.3 months; hazard ratio [HR], 1.87; 95% confidence interval [CI]: 1.01, 3.5; P = .04) and advanc

248 rasugrel group (hazard ratio [HR]: 1.41; 95% confidence interval [CI]: 1.04 to 1.90).

249 and maintenance (odds ratio [OR]: 1.26; 95% confidence interval [CI]: 1.12-1.41; Q < 0.001), and gre

250 te of referral (hazard ratio [HR]: 1.22; 95% confidence interval [CI]: 1.18-1.27), but lower evaluati

251 ymphadenopathy (relative risk [RR]: 1.7; 95% confidence interval [CI]: 1.2, 2.4; P = .002) and osseou

252 mia (univariate hazard ratio [HR]: 2.70; 95% confidence interval [CI]: 1.27 to 5.77; p = 0.01 vs. no/

253 ear mortality (hazard ratio [HR] = 2.11; 95% confidence interval [CI]: 1.48-3.03), with stronger asso

254 years; adjusted hazard ratio [HR]: 2.35; 95% confidence interval [CI]: 2.0 to 2.76; p < 0.001) and de

255 pre-term delivery (<37 weeks) was 2.47 (95% confidence interval [CI]: 2.16 to 2.82), and further str

256 of outcomes were as follows: HF: 3.18% (95% confidence interval [CI]: 2.83% to 3.57%) for sarcoidosi

257 nt yielded a pooled upgrade rate of 29% (95% confidence interval [CI]: 26%, 32%) for surgically excis

258 was longer in the BEV group (3.7 months; 95% confidence interval [CI]: 3.0, 4.2) compared with the no

259 D, and cerebrovascular disease was 40.8 (95% confidence interval [CI]: 40.3 to 41.3), 68.9 (95% CI: 6

260 Immune response of mOPV2 was 53.6% (95% confidence interval [CI]: 44.9%-62.1%) and 60.6% (95% CI

261 CIs were found in 61 of 105 skiers (58%; 95% confidence interval [CI]: 48.5%, 67.2%) compared with 28

262 p detection than conventional CT (58.8%; 95% confidence interval [CI]: 49.7%, 67.3%; 564 of 960 polyp

263 tor of matrix metalloproteinase 1 by 8% (95% confidence interval [CI]: 6% to 10%; p < 0.001), soluble

264 ghest-performing (baseline) SSD was 81% (95% confidence interval [CI]: 80%, 82%; 190 of 234) and PPV

265 ting a fracture of this model was 93.7% (95% confidence interval [CI]: 90.8%, 96.5%), with a sensitiv

266 n (>15%) with 98% accuracy (202 of 207) (95% confidence interval [CI]: 95%, 99%).

267 Specificity and sensitivity (including 95% confidence intervals [CI]) for each of the studied param

268 obstructive CAD: for the PTP model, 72 (95% confidence intervals [CI]: 71 to 74); for the RF-CL mode

269 .8% versus 4.7% [odds ratio {OR} = 5.05; 95% confidence interval {CI} = 3.01 to 8.46]; for males, 16.

270 eracillin/tazobactam (difference, -5.3% [95% confidence interval {CI}, -11.9% to 1.2%]), and favorabl

271 ormalized abundance (4-month mean, 0.71 [95% confidence interval {CI}, .2-1.2] and 6-month mean, 0.85

272 us ranibizumab (hazard ratio [HR], 0.96 [95% confidence interval {CI}, 0.74-1.25]; HR, 1.04 [95% CI,

273 hrHPV (adjusted odds ratio [aOR], 6.08 [95% confidence interval {CI}, 1.27-29.18], P = .02) and with

274 nt (multivariable odds ratio [mOR], 2.9 [95% confidence interval {CI}, 1.3-6.4]; P = .008), African o

275 24- and 6-fold higher (risk ratios, 24 [95% confidence interval {CI}, 10.8-62.3] and 6 [95% CI 1.5-2

276 ed 40 mg (clearance half-life 5.5 hours [95% confidence interval {CI}, 5.2-6.0 hours] vs 6.4 hours [9

277 tter 5-year OS (hazard ratio [HR], 0.53 [95% confidence interval {CI}: 0.29, 0.94]; HR, 0.40 [95% CI:

278 odds ratio, 2.0 per one-grade increase [95% confidence interval {CI}: 1.6, 2.4]; P < .001), carotid

279 000 enrollees per year for Medicare: 91 [95% confidence interval {CI}: 34, 148]; commercially insured

280 s of therapy discontinuation were 49.9% (95% confidence interval, CI 43.6-56.5) for pembrolizumab, 58

281 ater BMI loss [mean adjusted difference (95% confidence interval, CI) -3.1 kg/m (-4.4 to -1.9) kg/m,

282 ovided mean score differences (MDs) with 95% confidence intervals (CIs) for each HRQOL item and scale

283 stimated incidence rate ratios (RRs) and 95% confidence intervals (CIs) using Poisson regression, con

284 Rate ratios (RR) and 95% confidence intervals (CIs) were calculated comparing CVD

285 isks (RRs), standard mean differences of 95% confidence intervals (CIs) were calculated with the rand

286 Odds ratios (ORs) with 95% confidence intervals (CIs) were determined using logisti

287 tandardized incidence ratios (SIRs) with 95% confidence intervals (CIs).

288 alculate the prevalence ratios (PRs) and 95% confidence intervals (CIs).

289 timate summary relative risks (SRRs) and 95% confidence intervals (CIs).

290 The corresponding 95% confidence interval coverage rate ranged from 46.4% to 6

291 regression (odds ratio or hazard ratio, 95% confidence interval), diabetes (1.9, 1.4-3.0), pannicule

292 imated VI and blindness prevalence rates and confidence intervals for each survey measure and age gro

293 er concentrations in rats and within the 95% confidence interval of observed plasma silver concentrat

294 e population studies (odds ratio of 2.5, 95% confidence intervals of 1.4-4.4, P = 0.0013).

295 of OSA showed an adjusted hazard ratio (95% confidence interval) of 1.54 (1.06-2.24; P value = 0.02)

296 The adjusted proportion (95% confidence interval) of LTs paid by Medicaid among restr

297 The lower limit of the 2-sided 90% confidence interval was -1.724 letters, which is within

298 ority declared if the lower bound of the 95% confidence interval was greater than -12%.

299 A proportion metaanalysis (with 95% confidence interval) was performed using the random-effe

300 ferences or ratios (effect sizes) with their confidence intervals will be preferred.